FDA Approved: VABYSMO — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for VABYSMO (faricimab) from Genentech, Inc., regarding an updated indication or labeling. This action constitutes a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Neovascular Age-related Macular Degeneration

Drugs mentioned

• VABYSMO (faricimab)

Snippet

SUPPL AP for VABYSMO (FARICIMAB)